A decade of effective drug safety monitoring led by the BC-CfE

Leave a Comment / By /
  • For the past 10 years, the BC-CfE Pharmacovigilance Initiative has been monitoring antiretroviral-related adverse events to protect the safety of people taking medications for HIV treatment and prevention.
    Read more
  • Important contributions include publication of safety alerts, annual reports, and scientific literature, and supporting medication safety education.
    Read more

Leave a Reply

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below

Laboratory Order Forms

Start typing and press enter to search